Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design
Open Access
- 1 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 6 (1) , vdae039
Abstract
Background: Despite the lack of proven therapies for recurrent high-grade glioma (HGG), only 8%–11% of patients with glioblastoma participate in clinical trials, partly due to stringent eligibility criteria. Prior bevacizumab treatment is a frequent exclusion criterion, due to difficulty with response assessment and concerns for rebound edema following antiangiogenic discontinuation. There are no standardized trial eligibility rules related to prior antiangiogenic use. Methods: We reviewed ClinicalTrials.gov listings for glioma studies starting between May 2009 and July 2022 for eligibility rules related to antiangiogenics. We also reviewed the literature pertaining to bevacizumab withdrawal. Results: Two hundred and ninety-seven studies for patients with recurrent glioma were reviewed. Most were phase 1 (n = 145, 49%), non-randomized (n = 257, 87%), evaluated a drug-only intervention (n = 223, 75%), and had a safety and tolerability primary objective (n = 181, 61%). Fifty-one (17%) excluded participants who received any antiangiogenic, one (0.3%) excluded participants who received any non-temozolomide systemic therapy. Fifty-nine (20%) outlined washout rules for bevacizumab (range 2–24 weeks, 4-week washout n = 35, 12% most common). Seventy-eight required a systemic therapy washout (range 1–6 weeks, 4-week washout n = 34, 11% most common). Nine permitted prior bevacizumab use with limitations, 18 (6%) permitted any prior bevacizumab, 5 (2%) were for bevacizumab-refractory disease, and 76 (26%) had no rules regarding antiangiogenic use. A literature review is then presented to define standardized eligibility criteria with a 6-week washout period proposed for future trial design. Conclusions: Interventional clinical trials for patients with HGG have substantial heterogeneity regarding eligibility criteria pertaining to bevacizumab use, demonstrating a need for standardizing clinical trial design.Keywords
Funding Information
- National Center for Advancing Translational Sciences (R01 FD-R-07288)
This publication has 42 references indexed in Scilit:
- Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade gliomaJournal of Neuro-Oncology, 2010
- FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma MultiformeThe Oncologist, 2009
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology, 2009
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Salvage therapy with single agent bevacizumab for recurrent glioblastomaJournal of Neuro-Oncology, 2009
- Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver MetastasesJournal of Clinical Oncology, 2008
- Clinical pharmacokinetics of bevacizumab in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2008
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJournal of Clinical Investigation, 2006
- VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTSRetina, 2006
- MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapyNeurology, 2006